ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis

Company Overview

ImmunoPrecise Antibodies (NASDAQ: IPA) is a contract research organization focused on the discovery, development and optimization of antibodies. The company offers a full suite of services that span early‐stage discovery through to candidate selection, providing clients with monoclonal and polyclonal antibody solutions, custom immunochemistry assay development, and cell line engineering support. Leveraging multiple discovery platforms, ImmunoPrecise Antibodies tailors its approach to meet the unique requirements of therapeutic, diagnostic and research applications.

The company’s service offerings include hybridoma generation, phage display, single B cell screening and recombinant antibody engineering. These technologies enable rapid identification and humanization of high‐affinity antibody candidates. In addition, ImmunoPrecise Antibodies provides cell line development and protein expression support, helping clients to advance their molecules through scalable biomanufacturing processes and analytical characterization.

Headquartered in Victoria, British Columbia, ImmunoPrecise Antibodies maintains laboratories in North America, Europe and Asia Pacific to serve a global client base that ranges from emerging biotech firms to large pharmaceutical companies. Since its inception, the company has expanded its footprint through targeted facility investments, supporting projects across immuno‐oncology, autoimmunity, neuroscience and infectious disease research.

Under the leadership of President and CEO Dr. Paul R. Lem, PhD, ImmunoPrecise Antibodies has pursued strategic growth through both organic development and selective asset acquisitions. The management team combines expertise in antibody science, drug development and business operations, positioning the company to address evolving client needs in the rapidly advancing field of biotherapeutics.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.64 to $3.20
• 52-Week Range: N/A
• Volume: 1.97 million shs
• Average Volume: 1.83 million shs
• Market Capitalization: $96.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

ImmunoPrecise Antibodies Stock Analysis - MarketRank™

ImmunoPrecise Antibodies scored higher than 21% of companies evaluated by MarketBeat, and ranked 867th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ImmunoPrecise Antibodies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

ImmunoPrecise Antibodies has a consensus price target of $4.00, representing about 90.9% upside from its current price of $2.10.

Amount of Analyst Coverage

ImmunoPrecise Antibodies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ImmunoPrecise Antibodies are expected to grow in the coming year, from ($0.27) to ($0.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ImmunoPrecise Antibodies is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImmunoPrecise Antibodies is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ImmunoPrecise Antibodies has a P/B Ratio of 5.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for IPA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImmunoPrecise Antibodies does not currently pay a dividend.

Dividend Growth

ImmunoPrecise Antibodies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for IPA.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for IPA on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added ImmunoPrecise Antibodies to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ImmunoPrecise Antibodies insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.83% of the stock of ImmunoPrecise Antibodies is held by insiders.

Percentage Held by Institutions

Only 6.70% of the stock of ImmunoPrecise Antibodies is held by institutions.

IPA Stock Analysis - Frequently Asked Questions

How have IPA shares performed this year?

ImmunoPrecise Antibodies' stock was trading at $0.4117 at the start of the year. Since then, IPA stock has increased by 408.9% and is now trading at $2.0950.

How were ImmunoPrecise Antibodies' earnings last quarter?

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) issued its quarterly earnings results on Tuesday, July, 29th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.02. The company had revenue of $5.06 million for the quarter, compared to the consensus estimate of $7.89 million. ImmunoPrecise Antibodies had a negative trailing twelve-month return on equity of 40.62% and a negative net margin of 122.10%.
Read the conference call transcript.

How do I buy shares of ImmunoPrecise Antibodies?

Shares of IPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ImmunoPrecise Antibodies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoPrecise Antibodies investors own include NVIDIA (NVDA), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), GE Aerospace (GE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 10/10/2025
• Next Earnings (Estimated): 12/10/2025
• Fiscal Year End: 4/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IPA
• CIK: 1715925
• Web: www.immunoprecise.com
• Phone: 250-483-0308
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ImmunoPrecise Antibodies: $4.00
• High Price Target: $5.00
• Low Price Target: $3.00
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.68)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$21.69 million
• Net Margins: -122.10%
• Pretax Margin: -139.75%
• Return on Equity: -40.62%
• Return on Assets: -22.19%

Debt

• Debt-to-Equity Ratio: 0.49
• Current Ratio: 2.08
• Quick Ratio: 1.85

Sales & Book Value

• Annual Sales: $17.59 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.37 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 46,150,000
• Free Float: 43,002,000
• Market Cap: $96.68 million
• Optionable: Not Optionable
• Beta: 0.53